Non-alcoholic Fatty Liver Disease: all 1,507 studies

Page 9 of 16. Open to participants first (303), then studies with results posted, then the rest; newest registration first within each.

• MLCT Oil for Fatty Liver - PASS TrialStatus unknownNCT05217745Not applicable
• Healthy Liver - Healthy BrainCompletedNCT05216796Not applicable
• Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver DiseaseCompletedNCT05209100
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAR 502 in Healthy SubjectsWithdrawnNCT05203367Phase 1
• Pilot of Lifestyle Behavior Intervention for Non-Alcoholic Fatty Liver DiseaseCompletedNCT05200585Not applicable
• Impact Of Choline in Patients With NAFLDStatus unknownNCT05200156Not applicable
• Weight, Energy, Lipids, and the Liver (WELL) StudyActive, not recruitingNCT05199948Not applicable
• Semaglutide vs SitagliptinActive, not recruitingNCT05195944Phase 4
• Identification and Characterization of NAFLD in TurkeyCompletedNCT05194553
• Electrical Impedance Tomography in Fatty Liver DetectionCompletedNCT05189990
• Smartphone App for Non-alcoholic Fatty Liver DiseaseActive, not recruitingNCT05180760Not applicable
• Novel MRE Technique to Assess a Risk Factor for Liver CancerActive, not recruitingNCT05165446
• Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B PatientsActive, not recruitingNCT05147090Phase 4
• Effects of Mindfulness Based Stress Reduction Intervention in Patients With Non-alcoholic Fatty Liver DiseaseWithdrawnNCT05130346Not applicable
• Characterization of the Platelet Inflammatory Response in NAFL and NASHStatus unknownNCT05128253
• Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASHStatus unknownNCT05120557Not applicable
• Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASHWithdrawnNCT05118360Phase 2
• A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)CompletedNCT05117489Phase 1
• Development and Validation of a Multi-target, Blood-based NAFLD Diagnosis TestStatus unknownNCT05108415
• Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy ParticipantsCompletedNCT05107336Phase 1
• Serum Adiponectin as an Early Marker for Renal Impairment in Patients With Non-alcoholic Fatty Liver Disease.Status unknownNCT05106049
• A Study of ALG-055009 in Healthy Volunteers and Subjects With HyperlipidemiaCompletedNCT05090111Phase 1
• Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver DiseaseStatus unknownNCT05084404Phase 2
• Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) Study 1.2CompletedNCT05081427
• Effect of Indo-Mediterranean Diet on Hepatic Steatosis and Fibrosis in NAFLD ChildrenCompletedNCT05073588Not applicable
• Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver DiseaseActive, not recruitingNCT05067621Phase 2
• The Effect of Aerobic and Resistant Exercise Training in Patients With Non-Alcoholic SteatohepatitisStatus unknownNCT05065593Not applicable
• A Clinical Trial of XZP-6019 Tablets in Healthy SubjectsStatus unknownNCT05063968Phase 1
• Prevalence of Metabolic Liver Diseases in Patients With Type 1 Diabetes MellitusStatus unknownNCT05054712
• A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy ParticipantsCompletedNCT05053165Phase 1
• Study to Evaluate the Effectiveness of Legalon®CompletedNCT05051527
• Natural History of Non Alcoholic Fatty Liver Disease and Predictors of Advanced FibrosisWithdrawnNCT05050721
• Postprandial VLDL-triglyceride Metabolism in Type 2 Diabetes Patients With and Without NAFLDCompletedNCT05044130Not applicable
• The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin CapsulesCompletedNCT05042245Phase 4
• Anti-diabetic Drugs and Fatty Liver ManagementStatus unknownNCT05041673Not applicable
• Effects of Plant Sterols and Stanols on Liver InflammationStatus unknownNCT05037890Not applicable
• Economic Burden of NAFLDCompletedNCT05035043Not applicable
• Nonalcoholic Fatty Liver Disease in HIV DatabaseActive, not recruitingNCT05023044
• PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation CirrhosisCompletedNCT05022693Phase 1
• Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)CompletedNCT05016882Phase 2
• FTIH Study of ECC0509 in Healthy VolunteersCompletedNCT05012423Phase 1
• Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With FibrosisCompletedNCT05011305Phase 2
• ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)CompletedNCT05006885Phase 1
• Characteristics of NAFLD Among Type 2 Diabetes PatientsCompletedNCT04999124Not applicable
• Predicting Obesity Consequences Using Body Measure and Urine MetabolomicsStatus unknownNCT04989062
• "CAP" Fetge Gras. Lifestyle Modification Program in Catalonia.CompletedNCT04988633Not applicable
• Time Restricted Feeding on Nonalcoholic Fatty Liver Disease ( TREATY-FLD )：a 12-month Follow-up StudyCompletedNCT04988230Not applicable
• Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver DiseaseCompletedNCT04988204Not applicable
• NASH AMPK Exercise Dosing (AMPED) TrialCompletedNCT04987879Not applicable
• COVID-19 and Nonalcoholic Fatty Liver DiseaseCompletedNCT04982328
• Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) PatientsCompletedNCT04977661Phase 4
• Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty LiverStatus unknownNCT04976283Phase 4
• Pemvidutide (ALT-801) DDI Study in Healthy VolunteersCompletedNCT04972396Phase 1
• A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)Active, not recruitingNCT04951219Phase 3
• Clinical, Biochemical and Body Composition Analysis in Assessment of Steatosis in Non Alcoholic Fatty Liver DiseaseStatus unknownNCT04946786
• Effect of F. Prausnitzii on Glycemic ControlStatus unknownNCT04938843Not applicable
• A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224CompletedNCT04932512Phase 2
• A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy VolunteersCompletedNCT04931147Phase 1
• A Phase I Clinical Trial of XZP-5610 Tablets in Healthy SubjectsStatus unknownNCT04913090Phase 1
• Development and Evaluation of a Glucagon Sensitivity Test in Individuals With and Without Hepatic SteatosisCompletedNCT04907721Not applicable
• Bariatric Endoscopy and NAFLDActive, not recruitingNCT04895943
• Study on GS300 on NAFLDStatus unknownNCT04887766Not applicable
• First-in-Human Study of SRT-015 in Healthy Subjects.CompletedNCT04887038Phase 1
• Effects of Aerobic Exercise on Lean Non-alcoholic Fatty Liver Disease (NAFLD)CompletedNCT04882644Not applicable
• Safety, Tolerability, and Efficacy of AXA1125 in NASH With FibrosisStatus unknownNCT04880187Phase 2
• A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an ExtensionCompletedNCT04880031Phase 2
• Mobile Health Delivered Lifestyle Intervention Program in Patients With NASHCompletedNCT04872777Not applicable
• Effect of L-Citrulline Supplementation on NAFLD in Adolescents With ObesityCompletedNCT04871360Not applicable
• Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLDActive, not recruitingNCT04861571Not applicable
• Screening for Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD) at Al-Rajhy Hospital Nutrition Clinic. Assiut, EgyptStatus unknownNCT04861012Not applicable
• The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid TurnoverCompletedNCT04859322Not applicable
• Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver DiseaseCompletedNCT04857606Phase 1
• Effect of Fatty Liver Disease on Bone DensityStatus unknownNCT04850547
• A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )Active, not recruitingNCT04849728Phase 3
• DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.CompletedNCT04845646Phase 1
• Effect of Mediterranean Diet in Obese Adolescents With Nonalcoholic Fatty Liver DiseaseCompletedNCT04845373Not applicable
• Dairy Protien Rich Diet for NAFLD PatientsCompletedNCT04841915Not applicable
• Interest of APA in Fatty Liver Disease Evaluation of Efficacy and Adherence to an Adapted Physical Activity (APA) Program in Patients With Metabolic Fatty Liver DiseaseActive, not recruitingNCT04835831Not applicable
• Serum Selenium and Zinc Levels in Non-alcoholic Fatty Liver Disease PatientsCompletedNCT04834063
• Estrogen Administration for the Treatment of NASH in Postmenopausal WomenActive, not recruitingNCT04833140Phase 3
• The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy SubjectsCompletedNCT04829123Phase 1
• Efficacy and Safety of a Probiotic Composition as Adjunct in MAFL ManagementCompletedNCT04823676Not applicable
• Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)Active, not recruitingNCT04822181Phase 3
• Gut Microbiota in Chronic Noncommunicable DiseasesCompletedNCT04820556
• A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)Active, not recruitingNCT04820036Not applicable
• A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLDCompletedNCT04812262Phase 1
• A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects.CompletedNCT04808154Phase 1
• Effects of Intermittent Fasting on Fatty Liver DiseaseCompletedNCT04795973Not applicable
• Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIVActive, not recruitingNCT04795219
• Low-Calorie Diet in People With Prediabetes/Metabolic SyndromeCompletedNCT04786418Not applicable
• Accuracy of Imaging Techniques in Diagnosing Steatohepatitis and Fibrosis in NAFLD PatientsCompletedNCT04785937Not applicable
• Plant Stanols and Liver Inflammation in Overweight and Obese ChildrenStatus unknownNCT04783116Not applicable
• Non-invasive Ultrasound Diagnosis of Chronic Liver Diseases in Hepatology ConsultationCompletedNCT04782050Not applicable
• Chronic Kidney Disease and Non-alcoholic Fatty Liver DiseasesCompletedNCT04779905
• Correlation Between Hepatic Fibrosis and Cardiovascular Risk Evaluated by Non-invasive Tests in Patients With NAFLDCompletedNCT04774302
• Study to Evaluate MET642 in Patients With NASHCompletedNCT04773964Phase 2
• Effects of Febuxostat for Lowering Uric Acid in NAFLD Patients With GoutStatus unknownNCT04772352Phase 2
• A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver DiseaseTerminatedNCT04766476Phase 1
• Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver DiseaseWithdrawnNCT04761848Phase 1/2
• A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian MenCompletedNCT04722653Phase 1

← Non-alcoholic Fatty Liver Disease overview